SITE013-0056

completed

Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE013 (USA) (Dr. Clarke) · consented 2022-04-24

Adverse events

Serious AEs

Open data queries

Luna dropout signal

–

Adverse events

severe serious assessed 2026-08-18

Grade 3 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-06-21 (study day 40); relationship: N; serious criteria: hospitalization

severe assessed 2026-08-18

Grade 3 Pruritus — outcome: RECOVERED/RESOLVED; onset 2022-07-06 (study day 55); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-10-15 (study day 156); relationship: not assessed

severe serious assessed 2026-08-18

Grade 3 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-12-15 (study day 217); relationship: N; serious criteria: hospitalization

mild assessed 2026-08-18

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-12-29 (study day 231); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-01-25 (study day 258); relationship: not assessed

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.